Prospect: information for the user
Ferant 250 micrograms injectable solution EFG
palonosetrón
Read this prospect carefully before starting to use this medication,because it contains important information for you.
-This medication has been prescribedonlyto you, and you should not give it to other people even iftheyhave the same symptomsas you,as it may harm them.
1.What is Ferant and for what it is used
2.What you need to knowbeforestarting touse Ferant
3.How to use Ferant
4.Possible adverse effects
5Storage of Ferant
6.Contents of the package and additional information
Ferant contains the active ingredient palonosetrón. This belongs to a group of medicines called serotonin antagonists (5HT3).
Ferantis used in adults, adolescents, and children over 1 month of age to prevent general discomfort (nausea and vomiting) when receiving cancer treatments known as chemotherapy.
This medicine works by blocking the action of a chemical called serotonin, which can cause nausea or vomiting.
- If you are allergic to palonosetron or any of the other components of this medication (listed in section 6).
Do not be given Ferant if the above applies to you. In case of doubt, consult your doctor or nurse before being administered this medication.
Warnings and precautions
Consult your doctor or nurse before starting to use Ferant:
If any of the above points apply to you (or if you have doubts), consult your doctor or nurse before being administered this medication.
Use of Ferantwithother medications
Inform your doctor or nurse if you are using, have used recentlyor may have to use any other medication.Specifically, inform them if you are taking the following medications:
Depression or anxiety medications
Inform your doctor or nurse if you are taking any medication for depression or anxiety, including:
Medications that can affect your heart rhythm
Inform your doctor or nurse if you are taking any medication that affects your heart rhythm. This is because these medications can cause heart rhythm problems when taken with Ferant. These medications are:
If any of the above points apply to you (or if you have doubts), consult your doctor or nurse before being administered Ferant - this is because these medications can cause heart rhythm problems when taken with Ferant.
Pregnancy and breastfeeding
Pregnancy
If you are pregnant or think you may be pregnant, your doctor will not give you Ferant unless it is clearly necessary.This is because we do not know if Ferant is harmful to the baby.
Consult your doctor or nurse beforebeing administered thismedication if you are pregnant or think you may be pregnant.
Breastfeeding
We do not know if Ferant is present in breast milk.
Consult your doctor or nurse before being administered this medication if you are breastfeeding.
Driving and operating machinery
You may feel dizzy or tired after being administered this medication. If this happens, do not drive or use tools or machinery.
Ferant contains sodium
This medication contains 0.20 mmol (or 4.65 mg) of sodium per dose (up to 1.2 mmol or 27.9 mg for the highest dose), which should be taken into account in the treatment of patients with low-sodium diets.
A doctor or nurse will normally administer Ferant to you.
Adults
Children and adolescents (from 1 month to 17 years of age)
It is not recommended that you receive Ferant on the days following chemotherapy unless you are about to receive another cycle of chemotherapy.
If you have any other questions about the use of this medication, ask your doctor or nurse.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
The following side effects may occur with this medicine:
Severe side effects
Inform your doctor immediately if you observe any of the following severe side effects:
Inform your doctor immediately if you observe any of the severe side effects mentioned above.
Other side effects
Inform your doctor if you observe any of the following side effects:
Adults
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Inform your doctor if you observe any of the side effects mentioned above.
Side effects observed in tests (may affect up to 1 in 100 people):
Rare(may affect up to 1 in 10,000 people):
Children and young people
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Inform your doctor if you observe any of the side effects mentioned above.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:www.notificaRAM.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears onthe label on the box,after CAD. The expiration date is the last day of the month indicated.
This medication does not require any special storage temperature.Store the ampule in the outer packaging to protect it from light.
For single use, any remaining solution must be disposed of without use.
Medicines should not be thrown away through drains or in the trash. Ask your pharmacisthow to dispose ofthecontainers and themedicines that you no longerneed. This will help protect the environment.
Each milliliter of solution contains 50 micrograms of palonosetron. Each ampule of 5 milliliters of solution contains 250 micrograms of palonosetron.
Appearance of the product and contents of the packaging
Ferant injectable solution is a transparent and colorless solution and is presented in transparent glass ampules, which contain 5 milliliters of the solution.
Packagings containing 1, 5 or 10 ampules.
Only some sizes of packaging may be marketed.
Holder of the marketing authorization
Medochemie Ltd
1-10 Constantinoupoleos street
3011 Limassol
Cyprus
Responsible for manufacturing
Medochemie Ltd
48 Iapetou Street,
Agios Athanassios Industrial Area,
Agios Athanassios, 4101 Limassol
Cyprus
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Saniproject, S.L.
C/ Retamas 11 – Urb.Puentelasierra
28210 Valdemorillo, Madrid
SPAIN
Date of the last review of thisleaflet: November 2021
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.